AU2001272491A1 - Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest - Google Patents
Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interestInfo
- Publication number
- AU2001272491A1 AU2001272491A1 AU2001272491A AU7249101A AU2001272491A1 AU 2001272491 A1 AU2001272491 A1 AU 2001272491A1 AU 2001272491 A AU2001272491 A AU 2001272491A AU 7249101 A AU7249101 A AU 7249101A AU 2001272491 A1 AU2001272491 A1 AU 2001272491A1
- Authority
- AU
- Australia
- Prior art keywords
- thioredoxin
- polypeptide
- interest
- fusion proteins
- triple fusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000002933 Thioredoxin Human genes 0.000 title 1
- 102000044159 Ubiquitin Human genes 0.000 title 1
- 108090000848 Ubiquitin Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 108060008226 thioredoxin Proteins 0.000 title 1
- 229940094937 thioredoxin Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0015619 | 2000-06-26 | ||
GB0015619A GB0015619D0 (en) | 2000-06-26 | 2000-06-26 | Novel method |
GB0026484 | 2000-10-30 | ||
GB0026484A GB0026484D0 (en) | 2000-10-30 | 2000-10-30 | Novel system |
PCT/EP2001/006952 WO2002000892A1 (en) | 2000-06-26 | 2001-06-19 | Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001272491A1 true AU2001272491A1 (en) | 2002-01-08 |
Family
ID=26244545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001272491A Abandoned AU2001272491A1 (en) | 2000-06-26 | 2001-06-19 | Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest |
Country Status (6)
Country | Link |
---|---|
US (1) | US20030104570A1 (en) |
EP (1) | EP1294905A1 (en) |
JP (1) | JP2004501648A (en) |
AU (1) | AU2001272491A1 (en) |
CA (1) | CA2412084A1 (en) |
WO (1) | WO2002000892A1 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4088584B2 (en) | 2001-07-26 | 2008-05-21 | アドバンスド プロテイン テクノロジーズ コーポレイション | A method for separating a target protein from a fusion protein. |
WO2005026375A2 (en) | 2003-05-22 | 2005-03-24 | Fraunhofer Usa, Inc. | Recombinant carrier molecule for expression, delivery and purification of target polypeptides |
TWI305230B (en) * | 2004-06-25 | 2009-01-11 | Univ Feng Chia | Nucleic acid construct and expression vector for enhancing the production of recombinant protein, and method for the massive production of recombinant protein |
DK1853305T3 (en) * | 2005-02-04 | 2014-12-01 | Survac Aps | Survivin-peptide vaccine |
CA2616859C (en) | 2005-08-03 | 2015-04-14 | Fraunhofer Usa, Inc. | Compositions and methods for production of immunoglobulins |
US20080279877A1 (en) * | 2006-02-13 | 2008-11-13 | Fraunhofer U.S.A. Inc. | HPV antigens, vaccine compositions, and related methods |
PT2476435T (en) | 2006-08-11 | 2018-03-05 | Life Sciences Res Partners Vzw | Immunogenic peptides and their use in immune disorders |
US8404252B2 (en) | 2007-07-11 | 2013-03-26 | Fraunhofer Usa, Inc. | Yersinia pestis antigens, vaccine compositions, and related methods |
US20110111395A1 (en) | 2008-02-14 | 2011-05-12 | Jean-Marie Saint-Remy | Cd4+cells with cytolytic properties |
EP2623125A1 (en) * | 2008-02-14 | 2013-08-07 | Life Sciences Research Partners VZW | Elimination of immune responses to viral vectors |
EP2247306B1 (en) | 2008-02-14 | 2018-04-18 | Life Sciences Research Partners VZW | Immunogenic control of tumours and tumour cells |
EP2244733B1 (en) | 2008-02-14 | 2015-06-17 | Life Sciences Research Partners VZW | Immunotherapy targeting intracellular pathogens |
EP2249855B1 (en) | 2008-02-14 | 2017-03-22 | Life Sciences Research Partners VZW | Immunogenic peptides and their use in transplantation |
AU2009214040B2 (en) * | 2008-02-14 | 2013-08-22 | Katholieke Universiteit Leuven | Strategies to prevent and/or treat immune responses to soluble allofactors |
AU2013270496B2 (en) * | 2008-02-14 | 2016-02-04 | Katholieke Universiteit Leuven | Immunogenic control of tumours and tumour cells |
WO2010037046A1 (en) | 2008-09-28 | 2010-04-01 | Fraunhofer Usa, Inc. | Humanized neuraminidase antibody and methods of use thereof |
WO2011041391A1 (en) | 2009-09-29 | 2011-04-07 | Fraunhofer Usa, Inc. | Influenza hemagglutinin antibodies, compositions, and related methods |
KR101643761B1 (en) * | 2009-12-04 | 2016-07-29 | 삼성전자주식회사 | Fusion protein comprising ubiquitin or ubiquitin-like protein, membrane transfer domain and biologically active molecule and uses thereof |
JP5954728B2 (en) | 2010-01-22 | 2016-07-20 | 国立研究開発法人科学技術振興機構 | Probe reagent for measuring protein degradation activity |
PL2643345T3 (en) | 2010-11-25 | 2021-08-16 | Imnate Sarl | Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination |
GB201201511D0 (en) | 2012-01-30 | 2012-03-14 | Univ Leuven Kath | Modified epitopes for boosting CD4+ T-cell responses |
GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
US10729791B2 (en) | 2015-05-18 | 2020-08-04 | Imcyse Sa | Animal models for evaluating pharmaceutical compounds |
CA2995771A1 (en) | 2015-09-25 | 2017-03-30 | Imcyse Sa | Improved methods and compounds for eliminating immune responses to therapeutic agents |
BR112018071466A2 (en) | 2016-04-19 | 2019-03-19 | Imcyse Sa | new immunogenic cd1d binding peptides |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2079229C (en) * | 1990-05-09 | 1999-09-14 | Alexander J. Varshavsky | Ubiquitin-specific protease |
US5270181A (en) * | 1991-02-06 | 1993-12-14 | Genetics Institute, Inc. | Peptide and protein fusions to thioredoxin and thioredoxin-like molecules |
US6235525B1 (en) * | 1991-05-23 | 2001-05-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof |
US5585245A (en) * | 1994-04-22 | 1996-12-17 | California Institute Of Technology | Ubiquitin-based split protein sensor |
TR199902053T2 (en) * | 1997-02-25 | 2000-04-21 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use. |
GB9717953D0 (en) * | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
-
2001
- 2001-06-19 US US10/296,770 patent/US20030104570A1/en not_active Abandoned
- 2001-06-19 JP JP2002506207A patent/JP2004501648A/en active Pending
- 2001-06-19 CA CA002412084A patent/CA2412084A1/en not_active Abandoned
- 2001-06-19 WO PCT/EP2001/006952 patent/WO2002000892A1/en not_active Application Discontinuation
- 2001-06-19 EP EP01951610A patent/EP1294905A1/en not_active Withdrawn
- 2001-06-19 AU AU2001272491A patent/AU2001272491A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2002000892A1 (en) | 2002-01-03 |
CA2412084A1 (en) | 2002-01-03 |
JP2004501648A (en) | 2004-01-22 |
US20030104570A1 (en) | 2003-06-05 |
EP1294905A1 (en) | 2003-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001272491A1 (en) | Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest | |
AU2001264563A1 (en) | Albumin fusion proteins | |
AU2002361642A1 (en) | Recombinant antibody fusion proteins and methods for detection of apoptotic cells | |
WO1999066054A3 (en) | Erythropoietin analog-human serum albumin fusion protein | |
AU2002214531A1 (en) | Proteins and nucleic acids encoding same | |
AU7274898A (en) | Recombinant antibody-enzyme fusion proteins | |
AU3562299A (en) | Inhibin-hbc fusion protein | |
AU2002332041A1 (en) | Albumin fusion proteins | |
AU2002217505A1 (en) | Process for producing recombinant protein and fused protein | |
AU9798398A (en) | Gfp-annexin fusion proteins | |
AU2001288390A1 (en) | Proteins and nucleic acids encoding same | |
WO2002072792A8 (en) | Heterologous fusion protein constructs comprising a leishmania antigen | |
AU2002344219A1 (en) | Fusion proteins of biologically active peptides and antibodies | |
AU2001291050A1 (en) | Viral chemokine-tumur antigen fusion proteins | |
AU1672499A (en) | Proteinase inhibitor fusion proteins | |
WO2002094870A8 (en) | Proteins and nucleic acids encoding same | |
AU2001239889A1 (en) | Polypeptides and nucleic acids encoding same | |
AU1183200A (en) | Novel gene encoding brain-specific membrane protein | |
AU2002365084A1 (en) | Method and reagent for the detection of proteins and peptides | |
AU2001280993A1 (en) | Tissue-associated proteins and their uses | |
AU2002211681A1 (en) | Proteins and nucleic acids encoding same | |
AU2002213954A1 (en) | Method for the selective modification of peptides and proteins | |
AU2002221380A1 (en) | Adapter protein and gene encoding it | |
AU2002230994A1 (en) | Proteins and nucleic acids encoding same | |
AU2001234896A1 (en) | Novel polypeptides and nucleic acids encoding same |